<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        79-171-11
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2011
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CARDIOPROL 10MG TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BISOPROLOL FUMARATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        23.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1055]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Dallah Health Care Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C07AB07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Before you take CARDIOPROL &nbsp; &nbsp;&nbsp;<br />3. How to take CARDIOPROL<br />4. Possible side effects &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<br />5. How to store CARDIOPROL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<br />6. Further information<br />1. WHAT CARDIOPROL IS AND WHAT IT IS USED FOR<br />The active substance in CARDIOPROL &nbsp;tablets is Bisoprolol fumarate. Bisoprolol fumarate belongs to group of medicines called beta-blockers. Beta-blocker protects heart from too much activity. This medicine works by affecting the body&rsquo;s response to some nerve impulses, especially in the heart. As a result, Bisoprolol fumarate slows down the heart rate and makes the heart more efficient at pumping blood around the body. Heart failure occurs when the heart muscle is weak and unable to pump enough blood to supply the body&rsquo;s need.<br />□ CARDIOPROL tablets are used in combination with other medicines to treat stable heart failure.&nbsp;<br />□ CARDIOPROL tablets are used to treat high blood pressure (Hypertension) and angina pectoris (Chest pain caused by blockages in the arteries that supply the heart muscle).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;You are allergic to Bisoprolol fumarate or any of the other ingredients of this medicine (listed in section 6).<br />□ You have severe asthma or severe chronic lung disease.<br />□ You have severe blood circulation problems in your limbs (such as Raynaud&rsquo;s syndrome), which may cause your fingers and toes to tingle or turn pale or blue<br />□ You have untreated phaeochromocytoma, which is a rare tumour of the adrenal gland (medulla)<br />□ You have metabolic acidosis, which is a condition when there is too much acid in the blood.<br />□ Acute heart failure or heart failure that suddenly becomes worse and / or that may require<br />hospital treatment<br />□ Slow heart rate<br />□ Very low blood pressure<br />□ Certain heart conditions causing a very slow heart rate or irregular heartbeat&nbsp;<br />□ Cardiogenic shock, which is an acute serious heart condition causing low blood pressure and circulatory failure.<br />Take special care with CARDIOPROL:<br />Talk to your doctor or pharmacist before taking this medicine. He or she may want to take special care (for example give additional treatment or perform more frequent checks) if you have any of the following conditions:<br />□ Diabetes &nbsp; &nbsp; &nbsp;<br />□ Strict fasting (fasting from solid food)<br />□ Certain heart diseases such as disturbances in heart rhythm or severe chest pain at rest (Prinzmetal&rsquo;s angina)<br />□ Kidney or liver problems &nbsp;&nbsp;<br />□ Less severe blood circulation problems in your limbs &nbsp;&nbsp;<br />□ Less severe asthma or chronic lung disease &nbsp; &nbsp;&nbsp;<br />□ History of a scaly skin rash (psoriasis) &nbsp; &nbsp; □ Tumour of the adrenal gland (phaeochromocytoma)<br />□ Thyroid disorder.<br />In addition, tell your doctor if you are going to have:<br />□ Desensitization therapy (for example for the prevention of hay fever), because CARDIOPROL tablets may make it more likely that you experience an allergic reaction, or such a reaction may be more severe<br />□ Anaesthesia (for example for surgery), because CARDIOPROL tablets may influence how your body reacts to this situation.<br />Taking other medicines with CARDIOPROL:<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<br />Do not take the following medicines with CARDIOPROL tablets without special advice from your doctor:<br />□ Medicines for controlling the blood pressure or medicines for heart problems (such as amiodarone, amlodipine, clonidine, digitalis glycosides, diltiazem, disopyramide, felodipine, flecainide, lidocaine, methyldopa, moxonidine, phenytoin, propafenone, quinidine, rilmenidine, verapamil)<br />□ &nbsp;Medicines for depression e.g. imipramine, amitriptyline, moclobemide<br />□ &nbsp;Medicines to treat mental illness e.g. phenothiazines such as levomepromazine<br />□ &nbsp;Medicines used for anaesthesia during an operation (see also &ldquo;Take special care with CARDIOPROL&rdquo;)<br />□ &nbsp;Medicines used to treat epilepsy e.g. barbiturates such as phenobarbital<br />□ &nbsp;Certain pain killers (for instance acetyl salicylic acid, diclofenac, indomethacin, ibuprofen, naproxen)<br />□ &nbsp;Medicines for asthma or medicines used for a blocked nose<br />□ Medicines used for certain eye disorders such as glaucoma (increased pressure in the eye) or used to widen the pupil of the eye<br />□ &nbsp;Certain medicines to treat clinical shock (e. g. adrenaline, dobutamine, noradrenaline)<br />□ &nbsp;Mefloquine, a medicine for malaria<br />□ &nbsp;All these drugs as well as bisoprolol may influence the blood pressure and/or heart function.<br />□ &nbsp;Rifampicin for the treatment of infections<br />□ Medicines to treat severe headaches or migraines (ergotamine derivatives).<br />Pregnancy and breastfeeding:<br />Pregnancy: There is a risk that use of CARDIOPROL tablets during pregnancy may harm the baby. If you are pregnant or planning to become pregnant, tell your doctor. He or she will decide whether you can take CARDIOPROL tablets during pregnancy&nbsp;<br />Breast-feeding: It is not known whether Bisoprolol passes into human breast milk. Therefore, breastfeeding is not recommended during therapy with CARDIOPROL tablets.<br />Driving and using machines:<br />The ability to drive or operate machinery may be affected, depending on how well you tolerate the medicine. Be especially careful at the beginning of the treatment, when the dose is increased or when the medication is changed, and when combined with alcohol.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or your pharmacist if you are not sure. Treatment with CARDIOPROL tablet requires regular medical check up. This is particularly important in the initiation of therapy and during dose increase.<br />CARDIOPROL tablet should be taken in the morning, with or without food. Swallow the tablet/s whole with some water and do not chew or crush them. The tablet can be divided into equal doses.<br />Treatment with CARDIOPROL tablet is usually prolonged.<br />Adult:<br />Chest pain and high blood pressure:<br />Your doctor will start the treatment with lowest possible dose (5 mg). Your doctor will monitor you closely at the start of treatment. Your doctor will increase your dose to obtain the best possible dosage for you.<br />The maximum recommended dose is 20 mg once per day.<br />Patient with kidney disease:<br />Patient with severe kidney disease should not exceed 10 mg of bisoprolol once daily. Please consult your doctor before starting to use this medicine.<br />Patient with liver disease:<br />Patient with severe liver disease should not exceed 10 mg of bisoprolol once daily. Please consult your doctor before starting to use this medicine.<br />Heart failure:<br />Before you start using CARDIOPROL tablet, you should already be taking other medicines for heart failure including any ACE inhibitor, a diuretic and (as an added option) a cardiac glycoside.<br />Treatment with CARDIOPROL tablet must be started at a low dose and increased gradually. Your doctor will decide how to increase the dose, and this will normally be done in the following way:<br />- 1.25 mg bisoprolol fumarate once daily for a week<br />- 2.5 mg bisoprolol fumarate once daily for a week<br />- 3.75 mg bisoprolol fumarate once daily for a week<br />- 5 mg bisoprolol fumarate once daily for four weeks<br />- 7.5 mg bisoprolol fumarate once daily for four weeks<br />- 10 mg bisoprolol fumarate once daily for maintenance (on-going) therapy.<br />The maximum recommended daily dose of bisoprolol fumarate is 10 mg.&nbsp;<br />Depending on how well you tolerate the medicine, the doctor may also extend the time between dose increases. If your condition gets worse or if you no longer tolerate the drug, it may be necessary to lower the dose again or to stop treatment. For some patients a maintenance dose lower than 10 mg bisoprolol fumarate may be sufficient. Your doctor will tell you what to do. If you have to stop the treatment entirely, your doctor will usually advice you to reduce the dose gradually, as otherwise your condition may become worse.<br />Use in children<br />CARDIOPROL tablet is not recommended for use in children.<br />Elderly patient<br />In general adjustment of the dose is not needed. It is recommended to start with lowest possible dose.<br />If you notice that the bisoprolol dose is too strong or does not work well enough, please consult your doctor or pharmacist.<br />If you take more CARDIOPROL tablet than you should<br />If you take too much medicine, or if a child has swallowed the medicine by mistake ask your doctor or hospital for assessing risk and advice. Take this leaflet and any tablet you still have with you. You may feel slow heartbeat, severe breathing difficulties, dizziness or tremor (due to decreased blood sugar).<br />If you forget to take CARDIOPROL tablet:<br />If you forget to take a dose, take it as soon as you remember it unless it is nearly time for your next dose. Do not take a double dose to make up for a forgotten dose.<br />If you stop taking CARDIOPROL tablet:<br />Do not stop treatment suddenly or change the recommended dose without talking to your doctor first.<br />If you need to stop treatment, it must be done gradually to avoid side effects.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />To prevent serious reaction, speak to a doctor immediately if a side effect is severe, occurs suddenly or gets worse rapidly. The most serious side effects are related to the heart function:<br />□ Slowing of heart rate (may affect up to 1 in 10 people with chronic heart failure&nbsp;</p><p>and may affect up to 1 in 100 people with hypertension or angina pectoris)<br />□ Worsening of heart failure (may affect up to 1 in 10 people with chronic heart failure and may affect up to 1 in 100 people with hypertension or angina pectoris)<br />□ Slow or irregular heartbeat (may affect more than 1 in 10 people with chronic heart failure)<br />□ Worsening of symptom of blockage of the main blood vessel to the legs, especially at the start of treatment (Frequency not stated).<br />If you feel dizzy or weak or have breathing difficulties, please contact your doctor as soon as possible.<br />Further side effects are listed below according to how frequently they may occur:<br />Common (may affect up to 1 in 10 people):<br />□ Tiredness*, feeling weak (In patient with chronic heart failure), dizziness*, headache*<br />□ Feeling of coldness or numbness in hands or feet<br />□ Low blood pressure, especially in patient with heart failure.<br />□ Stomach or intestine problem such as nausea, vomiting, diarrhea or constipation.<br />Uncommon (may affect up to 1 in 100 people):<br />□ Sleep disturbances &nbsp; &nbsp;&nbsp;<br />□ Depression &nbsp; &nbsp;<br />□ Breathing problems in patients with asthma or chronic lung disease<br />□ Muscle weakness, muscle cramps. &nbsp; &nbsp; &nbsp; □ Feeling weak (In patient with hypertension or angina pectoris )<br />Rare (may affect up to 1 in 1,000 people):<br />□ &nbsp;Hearing problems &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<br />□ &nbsp;Allergic runny nose (Blocked or runny nose)<br />□ &nbsp;Reduced tear flow (can be a problem if you wear contact lenses)<br />□ &nbsp;Inflammation of liver which may cause yellowing of the skin or whites of the eyes<br />□ &nbsp;Some blood test for liver function and fat content are different from normal value.<br />□ &nbsp;Allergy-like reactions such as itching, flush, rash<br />□ Impaired erection (Reduced sexual performance) &nbsp; &nbsp; &nbsp;<br />□ Nightmares, hallucinations &nbsp; &nbsp; &nbsp;<br />□ Fainting<br />Very rare (may affect up to 1 in 10,000 people):<br />□ Irritation and redness of eye (conjunctivitis) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<br />□ Hair loss<br />□ Appearance or worsening of scaly skin rash (psoriasis): Psoriasis like rash.<br />* if treated for high blood pressure or angina then these symptom occur especially at beginning of treatment, or if your dosage changes. They are generally mild or often disappear within 1 to 2 weeks<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;Keep out of the reach and sight of children.<br />□ &nbsp;Do not store above 30 &deg;C.&nbsp;<br />□ &nbsp;Do not use CARDIOPROL after the expiry date which is stated on the carton and on the blister, after (EXP).Date.<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Bisoprolol Fumarate. Each CARDIOPROL 5 and 10 Tablet contains Bisoprolol Fumarate 5 and 10 mg, respectively.<br />□ The other ingredients are:<br />- CARDIOPROL 5: Microcrystalline cellulose 50 micrometer and colloidal silicon dioxide, calcium hydrogen phosphate dihydrate, pregelatinized starch, crospovidone, magnesium stearate, opadry OY-8719 orange.<br />- &nbsp;CARDIOPROL 10: Microcrystalline cellulose 50 micrometer &nbsp;and colloidal silicon dioxide, calcium hydrogen phosphate dihydrate, pregelatinized starch, crospovidone, magnesium stearate, opadry OY-8413 yellow.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                CARDIOPROL 5 tablets are orange, circular, scored, shallow biconvex, film coated tablets debossed with “CA 5” on one side.  
□ CARDIOPROL 10 tablets are mustard, circular, scored, shallow biconvex, film coated tablets debossed with “CA 10” on one side.  
□ Boxes of 30 blistered Tablets of CARDIOPROL 5.
□ Boxes of 1000 blistered Tablets of CARDIOPROL 5.
□ Boxes of 30 blistered Tablets of CARDIOPROL 10.
□ Boxes of 1000 blistered Tablets of CARDIOPROL 10.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Saudi Arabia: To report any side effect(s): National Pharmacovigilance Center (NPC):&nbsp;<br />Fax: +966-11-205-7662,&nbsp;<br />SFDA Call center: 19999,&nbsp;<br />E-mail: npc.drug@sfda.gov.sa,&nbsp;<br />Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Issued in: October 2023

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>المادة الفعالة في أقراص كارديوبرول هي بيسوبرولول فيوماريت. ينتمي بيسوبرولول فيوماريت إلى مجموعة من الأدوية تسمى حاصرات بيتا. تحمي حاصرات بيتا القلب من كثرة النشاط. يعمل هذا الدواء من خلال التأثير على استجابة الجسم لبعض النبضات العصبية وخاصة في القلب. نتيجة لذلك، يبطئ بيسوبرولول فيوماريت معدل ضربات القلب ويجعل القلب أكثر كفاءة في ضخ الدم في جميع أنحاء الجسم. يحدث فشل القلب عندما تكون عضلة القلب ضعيفة وغير قادرة على ضخ ما يكفي من الدم لإمداد الجسم باحتياجاته.<br />□ تستخدم أقراص كارديوبرول مع أدوية أخرى لعلاج قصور القلب المستقر.<br />□ تستخدم أقراص كارديوبرول لعلاج ارتفاع ضغط الدم &nbsp;والذبحة الصدرية (ألم في الصدر ناتج عن انسداد الشرايين التي تغذي عضلة القلب).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>□ إذا كان لديك حساسية من بيسوبرولول فيوماريت أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).<br />□ إذا كان لديك ربو شديد أو مرض رئوي مزمن شديد.<br />□ إذا كان لديك مشاكل شديدة في الدورة الدموية في أطرافك (مثل متلازمة رينود)، والتي قد تؤدي إلى وخز أصابع يديك وأصابع قدمك أو تحولها إلى اللون الشاحب أو الأزرق<br />□ إذا كنت تعاني من ورم القواتم غير المعالج، وهو ورم نادر في الغدة الكظرية (النخاع).<br />□ إذا كنت تعاني من الحماض الاستقلابي، وهي حالة تكثر فيها نسبة الحمض في الدم.<br />□ قصور القلب الحاد أو قصور القلب الذي يتفاقم فجأة و/ أو قد يتطلب ذلك العلاج في المستشفى<br />□ بطء معدل ضربات القلب<br />□ انخفاض شديد في ضغط الدم<br />□ أمراض قلبية معينة تؤدي إلى بطء شديد في معدل ضربات القلب أو عدم انتظام ضربات القلب<br />□ صدمة قلبية، وهي حالة قلبية خطيرة تؤدي إلى انخفاض ضغط الدم وفشل الدورة الدموية.<br />الاحتياطات عند استعمال كارديوبرول:&nbsp;<br />تحدث إلى طبيبك أو الصيدلي قبل تناول هذا الدواء. قد يرغب هو أو هي في الحصول على رعاية خاصة (على سبيل المثال، تقديم علاج إضافي أو إجراء فحوصات أكثر تكرارًا) إذا كان لديك أي من الحالات التالية:<br />□ مرض السكري<br />□ الصيام الصارم (الصيام من الطعام الصلب)<br />□ أمراض قلبية معينة مثل الاضطرابات في نظم القلب أو ألم شديد في الصدر أثناء الراحة (ذبحة برنزميتال)<br />□ مشاكل في الكلى أو الكبد<br />□ مشاكل أقل حدة في الدورة الدموية في أطرافك، ربو أقل حدة أو مرض رئوي مزمن.<br />□ تاريخ مرضي بالإصابة بطفح الجلد التقشري (الصدفية)<br />□ ورم في الغدة الكظرية (النخاع) (ورم القواتم)<br />□ اضطراب الغدة الدرقية.<br />بالإضافة إلى ذلك، أخبر طبيبك إذا كنت ستحصل على:<br />□ علاج إزالة التحسس (على سبيل المثال للوقاية من حمى القش)، لأن أقراص كارديوبرول قد تزيد من احتمالية تعرضك لرد فعل تحسسي، أو قد يكون رد الفعل هذا أكثر حدة.<br />□ التخدير (للجراحة على سبيل المثال)، لأن أقراص كارديوبرول قد تؤثر على كيفية تفاعل جسمك مع هذه الحالة.<br />تناول أدوية أخرى مع كارديوبرول:&nbsp;<br />أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.<br />لا تتناول الأدوية التالية مع أقراص كارديوبرول بدون استشارة خاصة من طبيبك:<br />□ أدوية للتحكم في ضغط الدم أو أدوية لمشاكل القلب (مثل أميودارون، أملوديبين، كلونيدين، ديجيتاليس جليكوسيدات، ديلتيازيم، ديسوبيراميد، فيلوديبين، فليكاينيد، ليدوكائين، ميثيل دوبا، موكسونيدين، فينيتوين، بروبافينون، كينيدين، فينيتوين).<br />□ أدوية لعلاج الاكتئاب مثل: إيميبرامين، أميتريبتيلين، موكلوبميد<br />□ أدوية لعلاج الأمراض العقلية مثل: الفينوثيازينات مثل ليفوميبرومازين<br />□ الأدوية المستخدمة للتخدير أثناء العملية (انظر أيضًا &quot;الاحتياطات عند استعمال كارديوبرول&quot;)<br />□ أدوية لعلاج الصرع مثل: الباربيتورات مثل الفينوباربيتال<br />□ بعض مسكنات الآلام (على سبيل المثال حمض أسيتيل ساليسيليك، ديكلوفيناك، إندوميثاسين، إيبوبروفين، نابروكسين)<br />□ أدوية للربو أو أدوية علاج انسداد الأنف<br />□ الأدوية المستخدمة لاضطرابات معينة في العين مثل الجلوكوما (زيادة الضغط في العين) أو المستخدمة لتوسيع حدقة العين.<br />□ أدوية معينة لعلاج الصدمة السريرية (مثل أدرينالين، دوبوتامين، نورادرينالين).<br />□ ميفلوكين دواء للملاريا<br />□ كل هذه الأدوية بالإضافة إلى بيسوبرولول قد تؤثر على ضغط الدم و/ أو وظائف القلب.<br />□ ريفامبيسين لعلاج الالتهابات<br />□ أدوية لعلاج الصداع الشديد أو الصداع النصفي (مشتقات الإرغوتامين).<br />الحمل و الرضاعة:<br />الحمل: هناك خطر من أن استخدام أقراص كارديوبرول أثناء الحمل قد يضر بالطفل. إذا كنت حاملاً أو تخططين للحمل، أخبري طبيبك. سيقرر هو أو هي ما إذا كان بإمكانك تناول أقراص كارديوبرول أثناء الحمل.<br />الرضاعة: من غير المعروف ما إذا كان بيسوبرولول يمر في حليب الأم. لذلك، لا ينصح بالرضاعة الطبيعية أثناء العلاج بأقراص كارديوبرول.<br />تأثير المستحضر على القيادة واستخدام الآلات:<br />قد تتأثر القدرة على القيادة أو تشغيل الآلات، اعتمادًا على مدى تحملك للدواء. كن حذرًا بشكل خاص في بداية العلاج ، عند زيادة الجرعة أو تغيير الدواء ، وعند الدمج مع الكحول.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>دائما تناول هذا الدواء تماما كما أخبرك طبيبك. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا. يتطلب العلاج باستخدام قرص كارديوبرول فحصًا طبيًا منتظمًا. هذا مهم بشكل خاص في بدء العلاج وأثناء زيادة الجرعة.<br />يجب تناول قرص كارديوبرول في الصباح، مع أو بدون طعام. ابتلع القرص/ الأقراص كاملة مع بعض الماء ولا تمضغها أو تسحقها. يمكن تقسيم القرص إلى جرعات متساوية. عادة ما يستغرق العلاج باستخدام أقراص كارديوبرول فترة طويلة.<br />الكبار:<br />آلام الصدر وارتفاع ضغط الدم:<br />سيبدأ طبيبك العلاج بأقل جرعة ممكنة (5 ملغم). سيراقبك طبيبك عن كثب في بداية العلاج. سيزيد طبيبك جرعتك للحصول على أفضل جرعة ممكنة لك.<br />الجرعة القصوى الموصى بها هي 20 ملغم مرة في اليوم.<br />مرضى الكلى:<br />يجب ألا يتجاوز المريض المصاب بمرض كلوي حاد 10 ملغم بيسوبرولول مرة واحدة يومياً. يرجى استشارة طبيبك قبل البدء في استخدام هذا الدواء.<br />مرضى الكبد:<br />يجب ألا يتجاوز المريض المصاب بمرض كبدي حاد عن 10 ملغم بيسوبرولول مرة واحدة يومياً. يرجى استشارة طبيبك قبل البدء في استخدام هذا الدواء.<br />قصور القلب:&nbsp;<br />قبل البدء باستخدام &nbsp;كارديوبرول، يجب أن تتناول بالفعل أدوية أخرى لفشل القلب بما في ذلك أي مثبط للإنزيم المحول للأنجيوتنسين ومدر للبول (كخيار إضافي) جليكوسيد القلب.<br />يجب أن يبدأ العلاج باستخدام كارديوبرول بجرعة منخفضة وزيادة تدريجية. سيقرر طبيبك كيفية زيادة الجرعة، ويتم ذلك عادةً بالطريقة التالية:<br />- 1.25 ملغم بيسوبرولول فيوماريت مرة واحدة يومياً لمدة أسبوع<br />- 2.5 ملغم بيسوبرولول فيوماريت مرة واحدة يومياً لمدة أسبوع<br />- 3.75 ملغم بيسوبرولول فيوماريت مرة واحدة يومياً لمدة أسبوع<br />- 5 ملغم بيسوبرولول فيوماريت مرة واحدة يومياً لمدة أربعة أسابيع<br />- 7.5 ملغم بيسوبرولول فيوماريت مرة واحدة يومياً لمدة أربعة أسابيع<br />- 10 ملغم بيسوبرولول فيوماريت مرة واحدة يومياً للعلاج المستمر.<br />الجرعة اليومية القصوى الموصى بها من بيسوبرولول فيوماريت هي 10 ملغم.<br />اعتمادًا على مدى تحملك للدواء، قد يقوم الطبيب أيضًا بتمديد الوقت بين زيادة الجرعة. إذا ساءت حالتك أو إذا لم تعد تحتمل الدواء، فقد يكون من الضروري خفض الجرعة مرة أخرى أو إيقاف العلاج. بالنسبة لبعض المرضى، قد تكون جرعة المداومة أقل من 10 ملغم بيسوبرولول فيوماريت كافية. سيخبرك طبيبك بما يجب عليك فعله. إذا كان عليك إيقاف العلاج تمامًا، فعادةً ما ينصحك طبيبك بتقليل الجرعة تدريجياً، وإلا فقد تصبح حالتك أسوأ.<br />الإستخدم في الأطفال<br />لا ينصح باستخدام &nbsp;كارديوبرول للأطفال.<br />المرضى المسنين<br />بشكل عام لا حاجة لتعديل الجرعة. من المستحسن أن تبدأ بأقل جرعة ممكنة.<br />إذا لاحظت أن جرعة بيسوبرولول قوية جدًا أو لا تعمل بشكل جيد، فيرجى استشارة الطبيب أو الصيدلي.<br />الجرعة الزائدة من كارديوبرول:<br />إذا كنت تتناول الكثير من الأدوية، أو إذا ابتلع طفل الدواء عن طريق الخطأ، اسأل طبيبك أو المستشفى لتقييم المخاطر والمشورة. خذ هذه النشرة وأي قرص لا يزال معك. قد تشعر بضربات قلب بطيئة، صعوبات شديدة في التنفس، دوخة أو رعشة (بسبب انخفاض نسبة السكر في الدم).<br />نسيان تناول جرعة كارديوبرول:<br />إذا نسيت تناول جرعة ، فتناولها بمجرد أن تتذكرها ما لم يكن الوقت قد حان لجرعتك التالية. لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية.<br />التوقف عن تناول كارديوبرول:&nbsp;<br />لا تتوقف عن العلاج فجأة أو تغير الجرعة الموصى بها دون التحدث مع طبيبك أولاً.<br />إذا كنت بحاجة إلى التوقف عن العلاج، فيجب أن يتم ذلك بشكل تدريجي لتجنب الآثار الجانبية.<br />إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.&nbsp;<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثاراً جانبية، على الرغم من عدم حدوثها لدى الجميع.<br />لمنع حدوث رد فعل خطير، تحدث إلى الطبيب على الفور إذا كان العرض الجانبي شديدًا أو حدث فجأة أو ساء بسرعة. ترتبط أخطر الآثار الجانبية بوظيفة القلب:<br />□ تباطؤ في معدل ضربات القلب (قد يؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص يعانون من قصور القلب المزمن وقد يؤثر على ما يصل إلى 1 من كل 100 شخص يعانون من ارتفاع ضغط الدم أو الذبحة الصدرية)<br />□ تفاقم قصور القلب (قد يؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص يعانون من قصور القلب المزمن وقد يؤثر على ما يصل إلى شخص واحد من كل 100 شخص يعانون من ارتفاع ضغط الدم أو الذبحة الصدرية).<br />□ بطء ضربات القلب أو عدم انتظامها (قد تؤثر على أكثر من شخص واحد من كل 10 أشخاص يعانون من قصور القلب المزمن).<br />□ تفاقم أعراض انسداد الأوعية الدموية الرئيسية في الساقين ، خاصة في بداية العلاج (التردد غير مذكور).<br />إذا شعرت بالدوار أو الضعف أو لديك صعوبات في التنفس ، يرجى الاتصال بطبيبك في أقرب وقت ممكن<br />المزيد من الآثار الجانبية ذكورة أدناه وفقًا لمدى تكرار حدوثها:<br />آثار جانبية شائعة (قد تظهر لدى ما يصل إلى شخص واحد من كل 10 أشخاص):<br />□ إرهاق * ، شعور بالضعف (لدى مرضى قصور القلب المزمن) ، دوار* ، صداع*<br />□ الشعور بالبرودة أو التنميل في اليدين أو القدمين<br />□ انخفاض ضغط الدم، خاصة عند مرضى قصور القلب.<br />□ مشاكل في المعدة أو الأمعاء مثل غثيان، قئ، إسهال أو إمساك.<br />آثار جانبية غير شائعة (قد تظهر لدى ما يصل إلى شخص واحد من كل 100 شخص):<br />□ إضطرابات في النوم.&nbsp;<br />□ إكتئاب.&nbsp;<br />□ مشاكل في التنفس لدى مرضى الربو أو أمراض الرئة المزمنة<br />□ ضعف عضلي ، تقلصات عضلية. &nbsp; &nbsp;&nbsp;<br />□ الشعور بالضعف (بالمريض الذي يعاني من ارتفاع ضغط الدم أو الذبحة الصدرية)<br />آثار جانبية نادرة (قد تظهر لدى ما يصل إلى شخص واحد من كل 1000 شخص):<br />□ مشاكل في السمع. &nbsp;<br />□ &nbsp;سيلان الأنف التحسسي (انسداد أو سيلان الأنف) &nbsp; &nbsp;□ انخفاض تدفق الدموع (يمكن أن يكون مشكلة إذا كنت ترتدي العدسات اللاصقة) &nbsp; &nbsp;<br />□ التهاب الكبد الذي قد يؤدي إلى اصفرار الجلد أو بياض العينين &nbsp;&nbsp;<br />□ تختلف بعض فحوصات الدم الخاصة بوظائف&nbsp;</p><p>الكبد ومحتوى الدهون عن القيمة الطبيعية. &nbsp;&nbsp;<br />□ ردود فعل تشبه الحساسية مثل الحكة، الاحمرار، الطفح الجلدي<br />□ ضعف الانتصاب (انخفاض الأداء الجنسي) &nbsp;&nbsp;<br />□ كوابيس، هلوسة &nbsp; &nbsp;&nbsp;<br />□ إغماء<br />آثار جانبية نادرة جدًا (قد تظهر لدى ما يصل إلى شخص واحد من بين 10000 شخص):<br />□ تهيج واحمرار العين (التهاب الملتحمة). &nbsp; &nbsp;<br />□ تساقط الشعر &nbsp;<br />□ ظهور أو تفاقم طفح جلدي متقشر (الصدفية): صدفية مثل الطفح الجلدي.<br />* إذا عولجت من ارتفاع ضغط الدم أو الذبحة الصدرية، فإن هذه الأعراض تظهر بشكل خاص في بداية العلاج ، أو إذا تغيرت جرعتك. تكون خفيفة بشكل عام أو تختفي غالبًا في غضون أسبوع إلى أسبوعين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;يحفظ بعيداً عن متناول الأطفال.&nbsp;<br />□ لا يحفظ بدرجة حرارة أعلى من 30&deg;م.&nbsp;<br />□ لا ينبغي استعمال كارديوبرول بعد تاريخ انتهاء الصلاحية الموجود على العلبة وعلى شريط الدواء.&nbsp;<br />لا ينبغي التخلص من الأدوية من خلال مياه الصرف الصحي أو المنزلي. اسأل الصيدلاني عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. سوف تساعد هذه الاجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي بيسوبرولول فيوماريت. كل قرص من كارديوبرول 5 و10 &nbsp;يحتوي على 5 و 10 ملغم بيسوبرولول فيوماريت على التوالي.<br />المكونات الأخرى هي:<br />□ كارديوبرول 5: سليلوز بلوري مكروي 50 ميكروميتر وثاني أكسيد السيليكون الغروي، كالسيوم هيدروجين فسفات دايهايدرات، نشا مجلتن مسبقاً، كروسبوفيدون، ستيارات المغنيزيوم، أوبادراي 8719 -OY &nbsp;برتقالي.<br />□ كارديوبرول 10: سليلوز بلوري مكروي &nbsp;ميكروميتر وثاني أكسيد السيليكون الغروي، كالسيوم هيدروجين فسفات دايهايدرات، نشا مجلتن مسبقاً، كروسبوفيدون، ستيارات المغنيزيوم، أوبادراي 8413 -OY &nbsp;أصفر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;أقراص كارديوبرول 5 هي أقراص برتقالية اللون، دائرية، محززة، مسطحة، ثنائية التحدب، مغلفة، منقوش عليها &ldquo;CA 5&rdquo; &nbsp;من جانب واحد.<br />□ أقراص كارديوبرول 10 هي أقراص خردلية اللون، دائرية، محززة، مسطحة، ثنائية التحدب، مغلفة، منقوش عليها &ldquo;CA 10&rdquo; &nbsp;من جانب واحد.<br />□ علب تحتوي على 30 قرص من أقراص كارديوبرول 5 المحفوظة في أشرطة.<br />□ علب تحتوي على 1000 قرص من أقراص كارديوبرول 5 المحفوظة في أشرطة.<br />□ علب تحتوي على 30 قرص من أقراص كارديوبرول 10 المحفوظة في أشرطة.<br />□ علب تحتوي على 1000 قرص من أقراص كارديوبرول 10 المحفوظة في أشرطة.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>المملكة العربية السعودية: للإبلاغ عن الأعراض الجانبية: المركزالوطني للتيقظ:&nbsp;<br />فاكس: 00966112057662،<br />مركز اتصال الهيئة العامة للغذاء والدواء (SFDA):19999،&nbsp;<br />البريد الإلكتروني: npc.drug@sfda.gov.sa، الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            صدرت في: تشرين الأول 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CARDIOPROL 10 film- coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active ingredient:

 Bisoprolol Fumarate 10 mg.

Inactive ingredients:

Ingredient	Quantity
mg/tab.
Microcrystalline Cellulose 50 micrometer and Colloidal Silicon Dioxide  	59.2
Calcium Hydrogen Phosphate Dihydrate 	41.6
Pregelatinized Starch	42.6
Crospovidone 	4.8
Magnesium Stearate	1.6
Opadry OY-8413 yellow	7.0

      *For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Mustard, circular scored shallow biconvex film coated tablets debossed with “CA 10” on one side and plain on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>q&nbsp; Management of hypertension</p><p>&nbsp;</p><p>q&nbsp; &nbsp;Management of angina pectoris.</p><p>&nbsp;</p><p>q&nbsp; Treatment of stable chronic heart failure with reduced systolic left ventricular function in addition to ACE inhibitors, and diuretics, and optionally cardiac glycosides (for additional information see section 5.1).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bisoprolol fumarate tablet should be taken in morning and can be taken with food in morning. They should be swallowed in liquid and should not be chewed.</p><p>&nbsp;</p><p><strong>Posology</strong></p><p>Treatment of hypertension and chronic stable angina pectoris</p><p>&nbsp;</p><p><strong>Adults</strong></p><p><strong>&nbsp;</strong></p><p>The dosage should be individually adjusted. It is recommended to start with 5 mg per day. The usual dose is 10 mg once daily with a maximum recommended dose of 20 mg per day.</p><p>&nbsp;</p><p><strong>Patients with renal impairment</strong></p><p><strong>&nbsp;</strong></p><p>In patients with severe renal impairment (creatinine clearance &lt; 20 ml/min) the dose should not exceed 10 mg once daily. This dosage may eventually be divided into halves.</p><p>&nbsp;</p><p><strong>Patients with severe liver impairment</strong></p><p>&nbsp;</p><p>No dosage adjustment is required; however careful monitoring is advised.</p><p>&nbsp;</p><p><strong>Discontinuation of treatment</strong></p><p><strong>&nbsp;</strong></p><p>Treatment should not be stopped abruptly (see section 4.4). The dosage should be diminished slowly by a weekly halving of the dose.</p><p>&nbsp;</p><p><strong>Treatment of stable chronic heart failure</strong></p><p><strong>Adults</strong></p><p><strong>&nbsp;</strong></p><p>Standard treatment of CHF consists of an ACE inhibitor (or an angiotensin receptor blocker in case of intolerance to ACE inhibitors), a beta-blocker, diuretics, and when appropriate cardiac glycosides. Patients should be stable (without acute failure) when bisoprolol treatment is initiated.</p><p>&nbsp;</p><p>It is recommended that the treating physician should be experienced in the management of chronic heart failure.</p><p>&nbsp;</p><p>Transient worsening of heart failure, hypotension, or bradycardia may occur during the titration period and thereafter.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Titration phase</strong></p><p><strong>&nbsp;</strong></p><p>The treatment of stable chronic heart failure with bisoprolol requires a titration phase</p><p>The treatment with bisoprolol is to be started with a gradual uptitration according to the following steps:</p><p>- 1.25 mg once daily for 1 week, if well tolerated increase to</p><p>- 2.5 mg once daily for a further week, if well tolerated increase to</p><p>- 3.75 mg once daily for a further week, if well tolerated increase to</p><p>- 5 mg once daily for the 4 following weeks, if well tolerated increase to</p><p>- 7.5 mg once daily for the 4 following weeks, if well tolerated increase to</p><p>- 10 mg once daily for the maintenance therapy.</p><p>The maximum recommended dose is 10 mg once daily.</p><p>Close monitoring of vital signs (heart rate, blood pressure) and symptoms of worsening heart failure is recommended during the titration phase. Symptoms may already occur within the first day after initiating the therapy.</p><p>&nbsp;</p><p><strong>Treatment modification</strong></p><p><strong>&nbsp;</strong></p><p>If the maximum recommended dose is not well tolerated, gradual dose reduction may be considered.</p><p>In case of transient worsening of heart failure, hypotension, or bradycardia reconsideration of the dosage of the concomitant medication is recommended. It may also be necessary to temporarily lower the dose of bisoprolol or to consider discontinuation.</p><p>The reintroduction and/or uptitration of bisoprolol should always be considered when the patient becomes stable again.</p><p>If discontinuation is considered, gradual dose decrease is recommended, since abrupt withdrawal may lead to acute deterioration of the patients condition.</p><p>Treatment of stable chronic heart failure with bisoprolol is generally a long-term treatment.</p><p>&nbsp;</p><p><strong>Special population</strong></p><p><strong>&nbsp;</strong></p><p><strong>Renal or hepatic impairment</strong></p><p><strong>&nbsp;</strong></p><p>There is no information regarding pharmacokinetics of bisoprolol in patients with chronic heart failure and with impaired hepatic or renal function. Uptitration of the dose in these populations should therefore be made with additional caution.</p><p>&nbsp;</p><p><strong>Elderly</strong></p><p><strong>&nbsp;</strong></p><p>No dosage adjustment is normally required.</p><p><strong>&nbsp;</strong></p><p><strong>Paediatric population</strong></p><p>There is no paediatric experience with bisoprolol, therefore its use cannot be recommended for children.</p><p>&nbsp;</p><p><strong>Method of administration</strong></p><p>&nbsp;</p><p>For oral use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bisoprolol is contraindicated in chronic heart failure patients with:
- Acute heart failure or during episodes of heart failure decompensation requiring i.v. Inotropic therapy
- 	Cardiogenic shock
- Second or third degree av block (without a pacemaker)
- Sick sinus syndrome
- Sinoatrial block
- Symptomatic bradycardia
- Symptomatic hypotension
- Severe bronchial asthma or severe chronic obstructive pulmonary disease
- Late stages of peripheral arterial occlusive disease and raynaud's syndrome
- Untreated phaeochromocytoma (see section 4.4)
- Metabolic acidosis
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Applies only to chronic heart failure:</strong></p><p><strong>&nbsp;</strong></p><p>The treatment of stable chronic heart failure with bisoprolol has to be initiated with special titration phase (see section 4.2).</p><p>&nbsp;</p><p><strong>Applies to all indications:</strong></p><p><strong>&nbsp;</strong></p><p>Especially in patients with ischemic heart disease the cessation of therapy with bisoprolol must not be done abruptly unless clearly indicated, because this may lead to transition worsening of heart condition (See section 4.2).</p><p>&nbsp;</p><p><strong>Precautions:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Applies only to hypertension or angina pectoris:</strong></p><p><strong>&nbsp;</strong></p><p>Bisoprolol must be used with caution in patients with hypertension or angina pectoris and accompanying heart failure.</p><p><strong>Applies only to chronic heart failure:</strong></p><p><strong>&nbsp;</strong></p><p>The initiation of treatment with bisoprolol necessitates regular monitoring. For posology and method of administration please (See section 4.2).</p><p>There is no therapeutic experience of bisoprolol treatment of heart failure in patients with the following diseases and conditions:</p><p>- insulin dependent diabetes mellitus (type I)</p><p>- severely impaired renal function</p><p>- severely impaired hepatic function</p><p>- restrictive cardiomyopathy</p><p>- congenital heart disease</p><p>- haemodynamically significant organic valvular disease</p><p>- myocardial infarction within 3 months</p><p><strong>&nbsp;</strong></p><p><strong>Applies to all indications:</strong></p><p>&nbsp;</p><p><strong>Bisoprolol must be used with caution in:</strong></p><p>- Bronchospasm (bronchial asthma, obstructive airways diseases).</p><p>&nbsp;</p><p>In bronchial asthma or other chronic obstructive lung diseases, which may cause symptoms, bronchodilating therapy is recommended to be given concomitantly. Occasionally an increase of the airway resistance may occur in patients with asthma, therefore the dose of beta2-stimulants may have to be increased.</p><p>&nbsp;</p><p>- Diabetes mellitus with large fluctuations in blood glucose values; symptoms of hypoglycaemia (e.g. tachycardia, palpitations or sweating) can be masked.</p><p>&nbsp;</p><p>- Strict fasting</p><p>&nbsp;</p><p>- Ongoing desensitisation therapy</p><p>&nbsp;</p><p>As with other beta-blockers, bisoprolol may increase both the sensitivity towards allergens and the severity of anaphylactic reactions. Adrenaline treatment does not always give the expected therapeutic effect.</p><p>&nbsp;</p><p>- First degree AV block</p><p>&nbsp;</p><p>- Prinzmetal&#39;s angina</p><p>&nbsp;</p><p>- Peripheral arterial occlusive disease (intensification of complaints might happen especially during the start of therapy)</p><p>&nbsp;</p><p>- General anaesthesia</p><p>&nbsp;</p><p>In patients undergoing general anaesthesia beta-blockade reduces the incidence of arrhythmias and myocardial ischemia during induction and intubation, and the post-operative period. It is currently recommended that maintenance beta-blockade be continued peri-operatively. The anaesthesist must be aware of beta-blockade because of the potential for interactions with other drugs, resulting in bradyarrhythmias, attenuation of the reflex tachycardia and the decreased reflex ability to compensate for blood loss. If it is thought necessary to withdraw beta-blocker therapy before surgery, this should be done gradually and completed about 48 hours before anaesthesia.</p><p>&nbsp;</p><p>Patients with psoriasis or with a history of psoriasis should only be given beta-blockers (e.g. bisoprolol) after carefully balancing the benefits against the risks.</p><p>&nbsp;</p><p>In patients with phaeochromocytoma bisoprolol must not be administered until after alpha-receptor blockade.</p><p>Under treatment with bisoprolol the symptoms of a thyreotoxicosis may be masked.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Applies only to chronic heart failure:</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Class I antiarrhythmic drugs (e.g. quinidine, disopyramide; lidocaine, phenytoin; flecainide, propafenone): Effect on atrio-ventricular conduction time may be potentiated and negative inotropic effect increased.</p><p>&nbsp;</p><p><strong>Applies to all indications:</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Calcium antagonists of the verapamil type and to a lesser extent of the diltiazem type: Negative influence on contractility and atrio-ventricular conduction. Intravenous administration of verapamil in patients on &beta;-blocker treatment may lead to profound hypotension and atrioventricular block.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Centrally acting antihypertensive drugs such as clonidine and others (e.g. methyldopa, moxonodine, rilmenidine): Concomitant use of centrally acting antihypertensive drugs may worsen heart failure by a decrease in the central sympathetic tonus (reduction of heart rate and cardiac output, vasodilation). Abrupt withdrawal, particularly if prior to beta-blocker discontinuation, may increase risk of &ldquo;rebound hypertension&rdquo;.</p><p>&nbsp;</p><p><strong>Combinations to be used with caution</strong></p><p><strong>&nbsp;</strong></p><p><strong>Applies only to hypertension or angina pectoris:</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Class-I antiarrhythmic drugs (e.g. quinidine, disopyramide; lidocaine, phenytoin; flecainide propafenone): Effect on atrio-ventricular conduction time may be potentiated and negative inotropic effect increased.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Applies to all indications</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Calcium antagonists of the dihydropyridine type such as felodipine and amlodipine: Concomitant use may increase the risk of hypotension, and an increase in the risk of a further deterioration of the ventricular pump function in patients with heart failure cannot be excluded.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Class-III antiarrhythmic drugs (e.g. amiodarone): Effect on atrio-ventricular conduction time may be potentiated.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Topical beta-blockers (e.g. eye drops for glaucoma treatment) may add to the systemic effects of bisoprolol.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Parasympathomimetic drugs: Concomitant use may increase atrio-ventricular conduction time and the risk of bradycardia.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Insulin and oral antidiabetic drugs: Increase of blood sugar lowering effect. Blockade of beta-adrenoreceptors may mask symptoms of hypoglycaemia.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaesthetic agents: Attenuation of the reflex tachycardia and increase of the risk of hypotension (for further information on general anaesthesia see also section 4.4.).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Digitalis glycosides: Reduction of heart rate, increase of atrio-ventricular conduction time.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-steroidal anti-inflammatory drugs (NSAIDs): NSAIDs may reduce the hypotensive effect of bisoprolol.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &beta;-Sympathomimetic agents (e.g. isoprenaline, dobutamine): Combination with bisoprolol may reduce the effect of both agents.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Sympathomimetics that activate both &beta;- and &alpha;-adrenoceptors (e.g. noradrenaline, adrenaline): Combination with bisoprolol may unmask the &alpha;-adrenoceptor-mediated vasoconstrictor effects of these agents leading to blood pressure increase and exacerbated intermittent claudication. Such interactions are considered to be more likely with nonselective &beta;-blockers.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Concomitant use with antihypertensive agents as well as with other drugs with blood pressure lowering potential (e.g. tricyclic antidepressants, barbiturates, phenothiazines) may increase the risk of hypotension.</p><p><strong>&nbsp;</strong></p><p><strong>Combinations to be considered</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mefloquine: increased risk of bradycardia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Monoamine oxidase inhibitors (except MAO-B inhibitors): Enhanced hypotensive effect of the beta-blockers but also risk for hypertensive crisis.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rifampicin: Slight reduction of the half-life of bisoprolol due to the induction of hepatic drugmetabolising enzymes. Normally no dosage adjustment is necessary.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ergotamine derivatives: Exacerbation of peripheral circulatory disturbances.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1-1-1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use during pregnancy</p><p>Bisoprolol has pharmacological effects that may cause harmful effects on pregnancy and/or the fetus/newborn. In general, beta-adrenoceptor blockers reduce placental perfusion, which has been associated with growth retardation, intrauterine death, abortion or early labour. Adverse effects (e.g. hypoglycaemia and bradycardia) may occur in the fetus and newborn infant. If treatment with beta-adrenoceptor blockers is necessary, beta1-selective adrenoceptor blockers are preferable.</p><p>Bisoprolol is not recommended during pregnancy unless clearly necessary. If treatment with bisoprolol is considered necessary, the uteroplacental blood flow and the fetal growth should be monitored. In case of harmful effects on pregnancy or the fetus alternative treatment should be reccomended. The newborn infant must be closely monitored. Symptoms of hypoglycaemia and bradycardia are generally to be expected within the first 3 days.</p><p>1-1-2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use during lactation</p><p>There are no data on the excretion of bisoprolol excreted in human milk. Therefore, breastfeeding is not recommended during administration of bisoprolol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In a study with coronary heart disease patients bisoprolol did not impair driving performance. However, due to individual variations in reactions to the drug, the ability to drive a vehicle or to operate machinery may be impaired. This should be considered particularly at start of treatment and upon change of medication as well as in conjunction with alcohol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following definitions apply to the frequency terminology used hereafter:</p><p>Very common (&ge; 1/10)</p><p>Common (&ge; 1/100, &lt; 1/10)</p><p>Uncommon (&ge; 1/1,000, &lt; 1/100)</p><p>Rare (&ge; 1/10,000, &lt; 1/1,000)</p><p>Very rare (&lt; 1/10,000)</p><p><u>Psychiatric disorders:</u></p><p>Uncommon: sleep disorders, depression.</p><p>Rare: nightmares, hallucinations.</p><p><u>Nervous system disorders:</u></p><p>Common: dizziness*, headache*</p><p>Rare: syncope</p><p><u>Eye disorders:</u></p><p>Rare: reduced tear flow (to be considered if the patient uses lenses).</p><p>Very rare: conjunctivitis.</p><p><u>Ear and labyrinth disorders:</u></p><p>Rare: hearing disorders.</p><p><u>Cardiac disorders:</u></p><p>Very common: bradycardia (in patients with chronic heart failure).</p><p>Common: worsening of pre-existing heart failure (in patients with chronic heart failure).</p><p>Uncommon: AV-conduction disturbances, worsening of pre-existing heart failure (in patients with hypertension or angina pectoris); bradycardia (in patients with hypertension or angina pectoris).</p><p><u>Vascular disorders:</u></p><p>Common: feeling of coldness or numbness in the extremities, hypotension especially in patient with heart failure.</p><p><u>Respiratory, thoracic and mediastinal disorders:</u></p><p>Uncommon: bronchospasm in patients with bronchial asthma or a history of obstructive airways disease.</p><p>Rare: allergic rhinitis.</p><p><u>Gastrointestinal disorders:</u></p><p>Common: gastrointestinal complaints such as nausea, vomiting, diarrhoea, constipation.</p><p><u>Hepatobiliary disorders:</u></p><p>Rare: hepatitis.</p><p><u>Skin and subcutaneous tissue disorders:</u></p><p>Rare: hypersensitivity reactions (such as itching, flush, rash).</p><p>Very rare: beta-blockers may provoke or worsen psoriasis or induce psoriasis-like rash, alopecia.</p><p><u>Musculoskeletal and connective tissue disorders:</u></p><p>Uncommon: muscular weakness and cramps.</p><p><u>Reproductive system and breast disorders:</u></p><p>Rare: potency disorders</p><p><u>General disorders:</u></p><p>Common: asthenia (in patients with chronic heart failure), fatigue*.</p><p>Uncommon: asthenia (in patients with hypertension or angina pectoris)</p><p><u>Investigations:</u></p><p>Rare: increased triglycerides, increased liver enzymes (ALAT, ASAT).</p><p><u>Applies only to hypertension or angina pectoris:</u></p><p>*These symptoms especially occur at the beginning of the therapy. They are generally mild and usually disappear within 1 - 2 weeks.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Saudi Arabia: To report any side effect(s): National Pharmacovigilance Center (NPC):&nbsp; Fax: +966-11-205-7662, SFDA Call center: 19999, E-mail: npc.drug@sfda.gov.sa, Website: https://ade.sfda.gov.sa</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most common signs expected with overdose of a beta-blocker are bradycardia, hypotension, bronchospasm, acute cardiac insufficiency and hypoglycaemia. There is limited experience with overdose of bisoprolol, only a few cases of overdose with bisoprolol have been reported. Bradycardia and/or hypotension were noted. All patients recovered. There is a wide inter-individual variation in sensitivity to one single high dose of bisoprolol and patients with heart failure are probably very sensitive.</p><p>In general, if overdose occurs, discontinuation of bisoprolol treatment and supportive and symptomatic treatment is recommended.</p><p>Based on the expected pharmacologic actions and recommendations for other beta-blockers, the following general measures may be considered when clinically warranted.</p><p>Bradycardia: Administer intravenous atropine. If the response is inadequate, isoprenaline or another agent with positive chronotropic properties may be given cautiously. Under some circumstances, transvenous pacemaker insertion may be necessary.</p><p>Hypotension: Intravenous fluids and vasopressors should be administered. Intravenous glucagon may be useful.</p><p>AV block (second or third degree): Patients should be carefully monitored and treated with isoprenaline infusion or temporary pacing..</p><p>Acute worsening of heart failure: Administer i.v. diuretics, inotropic agents, vasodilating agents.</p><p>Bronchospasm: Administer bronchodilator therapy such as isoprenaline, beta2-sympathomimetic drugs and/or aminophylline.</p><p>Hypoglycaemia: Administer i.v. glucose.</p><p>Limited data suggest that bisoprolol is hardly dialysable.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Beta blocking agents, selective</p><p>ATC Code: C07AB07</p><p><u>Mechanism of action</u></p><p>Bisoprolol is a potent highly beta<sub>1</sub>-selective-adrenoceptor blocking agent, lacking intrinsic stimulating and without relevant membrane stabilising activity. It only shows low affinity to the beta<sub>2</sub>-receptor of the smooth muscles of bronchi and vessels as well as to the beta<sub>2</sub>-receptors concerned with metabolic regulation. Therefore, bisoprolol is generally not to be expected to influence the airway resistance and beta<sub>2</sub>-mediated metabolic effects. Its beta<sub>1</sub>-selectivity extends beyond the therapeutic dose range.</p><p>Clinical efficacy and safety</p><p>In total 2647 patients were included in the CIBIS II trial. 83% (n = 2202) were in NYHA class III and 17% (n = 445) were in NYHA class IV. They had stable symptomatic systolic heart failure (ejection fraction &le;35%, based on echocardiography). Total mortality was reduced from 17.3% to 11.8% (relative reduction 34%). A decrease in sudden death (3.6% vs 6.3%, relative reduction 44%) and a reduced number of heart failure episodes requiring hospital admission (12% vs 17.6%, relative reduction 36%) was observed. Finally, a significant improvement of the functional status according to NYHA classification has been shown. During the initiation and titration of bisoprolol hospital admission due to bradycardia (0.53%), hypotension (0.23%), and acute decompensation (4.97%) were observed, but they were not more frequent than in the placebo-group (0%, 0.3% and 6.74%). The numbers of fatal and disabling strokes during the total study period were 20 in the bisoprolol group and 15 in the placebo group.</p><p>The CIBIS III trial investigated 1010 patients aged &ge;65 years with mild to moderate chronic heart failure (CHF; NYHA class II or III) and left ventricular ejection fraction &le;35%, who had not been treated previously with ACE inhibitors, beta-blockers, or angiotensin receptor blockers. Patients were treated with a combination of bisoprolol and enalapril for 6 to 24 months after an initial 6 months treatment with either bisoprolol or enalapril.</p><p>There was a trend toward higher frequency of chronic heart failure worsening when bisoprolol was used as the initial 6 months treatment. Non inferiority of bisoprolol-first versus enalapril-first treatment was not proven in the per-protocol analysis, although the two strategies for initiation of CHF treatment showed a similar rate of the primary combined endpoint death and hospitalization at study end (32.4% in the bisoprolol-first group vs. 33.1 % in the enalapril-first group, per-protocol population). The study shows that bisoprolol can also be used in elderly chronic heart failure patients with mild to moderate disease.</p><p><strong>&nbsp;</strong></p><p><strong>Hypertension or angina pectoris:</strong></p><p>Bisoprolol is used for the treatment of hypertension and angina pectoris. As with other Beta- 1-blocking agents, the method of acting in hypertension is unclear. However, it is known that Bisoprolol reduces plasma renin activity markedly.</p><p>Antianginal mechanism: Bisoprolol by inhibiting the cardiac beta receptors inhibits the response given to sympathetic activation. That results in the decrease of heart rate and contractility this way decreasing the oxygen demand of the cardiac muscle.</p><p>In acute administration in patients with coronary heart disease without chronic heart failure bisoprolol reduces the heart rate and stroke volume and thus the cardiac output and oxygen consumption. In chronic administration the initially elevated peripheral resistance decreases.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Beta blocking agents, selective</p><p>ATC Code: C07AB07</p><p><u>Mechanism of action</u></p><p>Bisoprolol is a potent highly beta<sub>1</sub>-selective-adrenoceptor blocking agent, lacking intrinsic stimulating and without relevant membrane stabilising activity. It only shows low affinity to the beta<sub>2</sub>-receptor of the smooth muscles of bronchi and vessels as well as to the beta<sub>2</sub>-receptors concerned with metabolic regulation. Therefore, bisoprolol is generally not to be expected to influence the airway resistance and beta<sub>2</sub>-mediated metabolic effects. Its beta<sub>1</sub>-selectivity extends beyond the therapeutic dose range.</p><p>Clinical efficacy and safety</p><p>In total 2647 patients were included in the CIBIS II trial. 83% (n = 2202) were in NYHA class III and 17% (n = 445) were in NYHA class IV. They had stable symptomatic systolic heart failure (ejection fraction &le;35%, based on echocardiography). Total mortality was reduced from 17.3% to 11.8% (relative reduction 34%). A decrease in sudden death (3.6% vs 6.3%, relative reduction 44%) and a reduced number of heart failure episodes requiring hospital admission (12% vs 17.6%, relative reduction 36%) was observed. Finally, a significant improvement of the functional status according to NYHA classification has been shown. During the initiation and titration of bisoprolol hospital admission due to bradycardia (0.53%), hypotension (0.23%), and acute decompensation (4.97%) were observed, but they were not more frequent than in the placebo-group (0%, 0.3% and 6.74%). The numbers of fatal and disabling strokes during the total study period were 20 in the bisoprolol group and 15 in the placebo group.</p><p>The CIBIS III trial investigated 1010 patients aged &ge;65 years with mild to moderate chronic heart failure (CHF; NYHA class II or III) and left ventricular ejection fraction &le;35%, who had not been treated previously with ACE inhibitors, beta-blockers, or angiotensin receptor blockers. Patients were treated with a combination of bisoprolol and enalapril for 6 to 24 months after an initial 6 months treatment with either bisoprolol or enalapril.</p><p>There was a trend toward higher frequency of chronic heart failure worsening when bisoprolol was used as the initial 6 months treatment. Non inferiority of bisoprolol-first versus enalapril-first treatment was not proven in the per-protocol analysis, although the two strategies for initiation of CHF treatment showed a similar rate of the primary combined endpoint death and hospitalization at study end (32.4% in the bisoprolol-first group vs. 33.1 % in the enalapril-first group, per-protocol population). The study shows that bisoprolol can also be used in elderly chronic heart failure patients with mild to moderate disease.</p><p><strong>&nbsp;</strong></p><p><strong>Hypertension or angina pectoris:</strong></p><p>Bisoprolol is used for the treatment of hypertension and angina pectoris. As with other Beta- 1-blocking agents, the method of acting in hypertension is unclear. However, it is known that Bisoprolol reduces plasma renin activity markedly.</p><p>Antianginal mechanism: Bisoprolol by inhibiting the cardiac beta receptors inhibits the response given to sympathetic activation. That results in the decrease of heart rate and contractility this way decreasing the oxygen demand of the cardiac muscle.</p><p>In acute administration in patients with coronary heart disease without chronic heart failure bisoprolol reduces the heart rate and stroke volume and thus the cardiac output and oxygen consumption. In chronic administration the initially elevated peripheral resistance decreases.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity or carcinogenicity.</p><p>Like other beta-blockers, bisoprolol caused maternal (decreased food intake and decreased body weight) and embryo/fetal toxicity (increased incidence of resorptions, reduced birth weight of the offspring, retarded physical development) at high doses but was not teratogenic.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>q&nbsp; Microcrystalline Cellulose 50 micrometer and Colloidal Silicon Dioxide&nbsp;</p><p>q&nbsp; Calcium Hydrogen Phosphate Dihydrate</p><p>q&nbsp; Pregelatinized Starch</p><p>q&nbsp; Crospovidone</p><p>q&nbsp; Magnesium Stearate</p><p>q&nbsp; Opadry OY-8413 yellow</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&ordm;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CARDIOPROL 10 Tablets are packed in boxes of 30 Tablets blistered in (PVC/PVDC) Aluminium Foil Blisters.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CARDIOPROL 10 Tablets are packed in boxes of 1000 Tablets blistered in (PVC/PVDC) Aluminium Foil Blisters.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Jordanian Pharmaceutical Manufacturing Co. Ltd.
PO Box 151
Um Al-Amad 16197
Jordan

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2023.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>